TICKERNERD
Menu
DYAIDYAIHealthcare · Biotechnology

DYAI Stock Forecast: Dyadic International, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$0.70
−0.07% on the day

The 1 Wall Street analysts covering Dyadic International, Inc. hold a median 12-month price target of $5.5 — +686.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 19 of 100 as at 22 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$27.6M
Ticker Nerd rank
19 / 100
Median analyst target
$5.50
Analysts covering
1
Total return, dividends reinvested
1W
−10.3%
1M
−52.4%
YTD
−25.6%
1Y
−10.3%
From 52W high
−52.4%
From 52W low
+2.9%
$0.68
$1.47
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

DYAI stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Dyadic International, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
19 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
87
Issuance
44
Volatility
44
Accruals
43
Value
34
Momentum
31
Revisions
27
Growth
24
Quality
13

Size (87): Smaller than most of the companies we track.

Quality (13): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

DYAI stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on DYAI, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00Oct 25Jan 26Apr 26Jul 26DYAIHigh $7.00Median $5.50Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $4.00Median $5.50High $7.00

The green dot is the last close — the median target sits +686.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
23 Oct 2025HC Wainwright & Co.AssumesBuy$3.00
14 Nov 2024HC Wainwright & Co.ReiteratesBuy—
8 July 2024HC Wainwright & Co.ReiteratesBuy—
13 Nov 2023HC Wainwright & Co.ReiteratesBuy—
24 May 2023HC Wainwright & Co.ReiteratesBuy—
3 Feb 2023HC Wainwright & Co.ReiteratesBuy—
18 July 2022Dawson JamesDowngradeNeutral—
5 Apr 2022HC Wainwright & Co.MaintainsBuy—
17 Dec 2021HC Wainwright & Co.InitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. DYAI appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

DYAI analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
2
Fundamentals

Dyadic International, Inc. (DYAI) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−3.0×

Cheaper than 87% of US stocks

Price / sales
7.3×

Cheaper than 18% of US stocks

Price / book
−61.6×

Cheaper than 99% of US stocks

EV / EBITDA
−3.9×

Cheaper than 77% of US stocks

Growth & margins
Revenue growth (YoY)
−0.6%

Higher than 27% of US stocks

Earnings growth (YoY)
240.6%

Higher than 91% of US stocks

Gross margin
−27.0%

Higher than 3% of US stocks

Operating margin
−212.8%

Higher than 10% of US stocks

Net margin
−200.5%

Higher than 2% of US stocks

Returns & dividend
Return on equity
−597.6%

Higher than 2% of US stocks

Return on assets
−63.0%

Higher than 6% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

DYAI vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
DYAIDyadic International, Inc.$27.6M
19
QNTMQuantum BioPharma Ltd.$27.0M
43
NXTCNextCure, Inc.$28.8M
76
LGVNLongeveron, Inc.$26.3M
33
ACTUActuate Therapeutics, Inc.$29.1M
27
BYSIBeyondSpring, Inc.$29.6M
21
LTRNLantern Pharma, Inc.$29.9M
56

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Dyadic International, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest DYAI news & analysis

Dyadic International, Inc. Secures $2.9 Million Through Registered Direct Offering and Concurrent Private Placement

GlobeNewsWire · 13 Aug 2026neutral

Dyadic International announced definitive agreements with an institutional investor to sell common stock in a registered direct offering and issue warrants in a concurrent private placement, securing $2.9 million. The company is a biotechnology firm developing recombinant protein solutions across life sciences, food and nutrition, bio-industrial and biopharmaceutical markets.

Why it matters — DYAI watchers would care because this capital raise adds funding to the company through the sale of new shares and warrants.

Dyadic International, Inc. (DYAI) Q2 2026 Earnings Call Transcript

Seeking Alpha · 13 Aug 2026neutral

Seeking Alpha published the transcript of Dyadic International, Inc.'s (DYAI) Q2 2026 earnings call. The item discloses that the company held its second-quarter earnings call and that the full transcript is now available.

Why it matters — Investors following DYAI can review the official earnings call transcript for management's commentary on the company's quarterly performance.

Dyadic Announces Second Quarter 2026 Financial Results Accelerating Commercialization Momentum Across Key Business Areas

GlobeNewsWire · 12 Aug 2026positive

Dyadic International reported its financial results for the second quarter ended June 30, 2026, highlighting significant progress in product commercialization, strategic partnerships, and expansion of its C1 biomanufacturing platform.

Why it matters — The Q2 2026 results provide DYAI watchers with an update on the company's commercialization momentum and strategic progress across its key business areas.

Dyadic Expands Commercial Non-Animal Dairy Pipeline Through New Strategic Development Agreement

GlobeNewsWire · 4 Aug 2026positive

Dyadic announced a new development and commercial license agreement with a European biotechnology company to add precision-fermented dairy proteins to its commercial non-animal dairy pipeline. The agreement expands Dyadic's offerings in the food and nutrition market.

Why it matters — A DYAI watcher would care because the agreement expands Dyadic's commercial non-animal dairy pipeline through a new partnership, broadening its reach in the food and nutrition sector.

Dyadic to Report Q2 2026 Financial Results and Host Conference Call on Wednesday August 12, 2026

GlobeNewsWire · 3 Aug 2026neutral

Dyadic International announced it will report its financial results for the quarter ended June 30, 2026, and host a corporate update conference call on Wednesday, August 12, 2026. The announcement was made August 3, 2026.

Why it matters — A Dyadic watcher would care because the upcoming earnings report and conference call will provide an update on the company's Q2 2026 financial performance and business operations.

FAQ

Frequently asked questions about DYAI stock

What is the DYAI stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Dyadic International, Inc. have a median 12-month price target of $5.5, with estimates ranging from $4 to $7. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is DYAI stock a buy right now?

Of the 1 analysts covering Dyadic International, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Dyadic International, Inc. 19 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank DYAI?

As at 22 Aug 2026, Dyadic International, Inc. ranks 19 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (87 of 100).

Will DYAI stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +686.3% from the last close, and Ticker Nerd's factor model ranks Dyadic International, Inc. 19 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the DYAI stock forecast for 2030?

No analyst covering Dyadic International, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DYAI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $7 over the next 12 months.

How has DYAI stock performed over the past year?

Dyadic International, Inc. returned -10.3% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Dyadic International, Inc. do?

Dyadic International Inc. is a global biotechnology company that develops and commercializes gene expression platforms for producing high-value proteins and industrial enzymes.

What is the latest news on DYAI?

The most recent item we track (GlobeNewsWire, 13 Aug 2026): "Dyadic International, Inc. Secures $2.9 Million Through Registered Direct Offering and Concurrent Private Placement". Dyadic International announced definitive agreements with an institutional investor to sell common stock in a registered direct offering and issue warrants in a concurrent private placement, securing $2.9 million. The company is a biotechnology firm developing recombinant protein solutions across life sciences, food and nutrition, bio-industrial and biopharmaceutical markets.

Company

About Dyadic International, Inc.

Dyadic International Inc. is a global biotechnology company that develops and commercializes gene expression platforms for producing high-value proteins and industrial enzymes. The company's proprietary C1 technology, based on the Thermothelomyces heterothallica fungus, enables the large-scale production of strategic input proteins for non-pharmaceutical applications. These proteins serve as essential components across the life sciences, food and nutrition, and bioindustrial sectors, supporting bioprocessing, formulation, and product development. By focusing on non-pharmaceutical applications, Dyadic International helps customers avoid the regulatory complexity and substantial costs associated with therapeutic biologics. The company has licensed its technology to major industry partners including BASF, Codexis, and Abengoa Bioenergy for use in industrial applications. Founded in 1979 and headquartered in Jupiter, Florida, Dyadic International operates as a platform provider enabling innovation across multiple high-growth markets.

CEO Mr. Mark A. Emalfarb · 5 employees · United States · https://www.dyadic.com